Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy. The post Breaking News: MAPS Files New Drug Application...
Cody Shandraw is a managing partner at Ambria Capital and Co-Founder of Healing REIT, both of which are working to provide better solutions to healthcare....
It is that time again when financial reports from the previous quarter start coming out. These documents let us know which companies are moving in a...
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. The...
Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of ibogaine derivative tabernanthalog. The post Terran...
For those interested in ketamine treatment, there is a vast array of potential therapies designed to meet you where you’re at.
European based biopharma MGC Pharmaceuticals has finalised a share consolidation and ~US$8 million funding as the company confidently looks towards the...
The firm says its existing cash will fund it through 2025. The post Compass Pathways Research, Clinical Trials Buoyed by Influx of New Funds appeared first...
–Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET – – Complete Phase 2...
This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint. The...